Loxo Oncol Eli Lilly Drug Patent Portfolio

Loxo Oncol Eli Lilly owns 1 orange book drug protected by 5 US patents Given below is the list of Loxo Oncol Eli Lilly's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10584124 Crystalline forms 10 Oct, 2038
Active
US10786489 Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile 10 Oct, 2038
Active
US10112942 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors 10 Oct, 2037
Active
US10137124 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors 10 Oct, 2037
Active
US10172851 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors 10 Oct, 2037
Active


Given below is the list of recent legal activities going on the following drug patents of Loxo Oncol Eli Lilly.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Yr, Small Entity 21 Feb, 2024 US10786489
Payment of Maintenance Fee, 4th Year, Large Entity 23 Aug, 2023 US10584124
Payment of Maintenance Fee, 4th Year, Large Entity 22 Jun, 2022 US10172851
Payment of Maintenance Fee, 4th Year, Large Entity 21 Apr, 2022 US10137124
Payment of Maintenance Fee, 4th Year, Large Entity 22 Mar, 2022 US10112942
Post Issue Communication - Certificate of Correction 25 Nov, 2020 US10786489
Sequence Moved to Public Database 29 Sep, 2020 US10786489
Recordation of Patent Grant Mailed 29 Sep, 2020 US10786489
Patent Issue Date Used in PTA Calculation 29 Sep, 2020 US10786489
Email Notification 15 Sep, 2020 US10786489
Issue Notification Mailed 09 Sep, 2020 US10786489
Dispatch to FDC 21 Aug, 2020 US10786489
Application Is Considered Ready for Issue 21 Aug, 2020 US10786489
Issue Fee Payment Verified 20 Aug, 2020 US10786489
Issue Fee Payment Received 20 Aug, 2020 US10786489


Loxo Oncol Eli Lilly's Family Patents

Loxo Oncol Eli Lilly drugs have patent protection in a total of 39 countries. It's US patent count contributes only to 27.0% of its total global patent coverage. Click below to unlock the full patent family tree.

Family Patents



Loxo Oncol Eli Lilly Drug List

Given below is the complete list of Loxo Oncol Eli Lilly's drugs and the patents protecting them.


1. Retevmo

Retevmo is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10584124 Crystalline forms 10 Oct, 2038
(14 years from now)
Active
US10786489 Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile 10 Oct, 2038
(14 years from now)
Active
US10112942 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors 10 Oct, 2037
(13 years from now)
Active
US10137124 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors 10 Oct, 2037
(13 years from now)
Active
US10172851 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors 10 Oct, 2037
(13 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Retevmo's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List